1 / 20

Recombinant EPO production–points the nephrologist should know

Recombinant EPO production–points the nephrologist should know. Wolfgang Jelkmann. Erythropoetin. Glycoprotein hormone that controls erythropoesis Produced by the peritubular capillary endothelial cells in the kidney. rhEPO.

jana-callahan
Download Presentation

Recombinant EPO production–points the nephrologist should know

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Recombinant EPO production–points the nephrologist should know Wolfgang Jelkmann

  2. Erythropoetin • Glycoprotein hormone that controls erythropoesis • Produced by the peritubular capillary endothelial cells in the kidney

  3. rhEPO • Provides enormous benefit in the prevention and reversal of anemia in chronic kidney disease, malignancy and AIDS • Supports autologous blood collection

  4. Source: http://www.sciprogen.com/en/products111.html

  5. rhEPO-type substances • Represent the largest market of a class of biopharmaceuticals • Global estimated sales of ~1010 euro (Php 600 x 1010) per annum

  6. EPO Formation • rhEPO is produced with the use of cells transfected with either the human EPO gene or EPO cDNA • Present therapeutic rhEPO preparations are manufactured in mammalian host cells • EPO is a complex glycoprotein of 165 amino acids to which four glycans are attached

  7. EPO Formation Addition of sugar molecules to dolichol ↓ Glycan transferred to growing polypeptide ↓ Folded and moved to Golgi complex ↓ N-acetylglucosamine, galactose and sialic acid (N-acetylneuraminic acid) finally added

  8. Nomenclature • Stem: “-poetin” • Epoietin: eucaryotic cell-derived rhEPO • Changes in the amino acid sequence indicated by a different prefix (eg: darbepoetin) • Analogues with an altered glycosylation pattern due to production in a different host cell system classified by a Greek letter added to the name (eg: epoetin-ω, epoetin-α)

  9. Nomenclature • Epoetins possess 3 tetra-antennary N-linked (Asn 24, 38 and 83) and 1 small O-linked (Ser 126) glycans • Carbohydrates amount to 40% of the total molecular mass of EPO (30.4 kDa) • Survival of EPO in circulation requires the presence of terminal sialic acid residues of its N-glycans • Asialo-glycoproteins are rapidly cleared via galactose-receptors of hepatocytes

  10. Differences between Epoetins • Chinese hamster ovary (CHO) cells deficient in the dihydrofolate reductase gene are most commonly used for the large-scale pharmaceutical manufacture of glycoproteins • CHO cell-derived products: • Epoetin-α (Epogen, Procrit, Eprex, Erypo, Espo) • Epoetin-β (Recormon, NeoRecormon, Epogin)

  11. Differences between Epoetins • Epoetin-α is more homogenous and possesses less basic isoforms than epoetin-β • Plasma half-life of epoetin-α was measuredto be shorter than that of epoetin-β by some investigators • The two established products are clinicallyequivalent • Transiently higherincidence of antibody formation towards an epoetin-αformulation (Eprex)

  12. Safety Considerations • The clinical efficacy and safety of biosimilar rhEPO preparations should be demonstrated in at least two adequately powered, randomized, parallel group clinical trials in comparison to a reference product • The transgene, the host cell line, the culture conditions and the purification procedures applied by a follow-on manufacturer cannot be the same as the original • The manufacturing process cannot be exactly copied

  13. Safety Considerations • Epoetin-ω (Epomax, Hemax): Expressed in baby hamster kidney cells • Amino acid sequence is unaltered • Has an N-glycan with phosphorylatedoligomannoside chains and it possesses lessO-glycans

  14. Safety Considerations • Epoetin-δ: expressed in the human fibrosarcoma cell line—HT 1080 derivative (others in lymphoblastoid RPMI 1788 cells) • Possesses less N-glycolylneuraminic acid residues (Neu5Gc) than CHO cell-derived epoetins

  15. EPO Congeners • Darbepoetin-α (Aranesp) • rhEPO mutein (a product with altered amino acid sequence) • increased molecular mass (37.1 kDa vs 30.4 kDa) and increased proportion of carbohydrate (51% vs 40%) • Lower affinity for the EPO receptor (EPO-R) but a longer survival in circulation • Terminal half-life: 3-4x lonnger than that of epoetin-α or epoetin-β (25 vs 6–9 h)

  16. EPO Congeners • Pegylated epoetin-β (CERA, ‘continuous erythropoiesis receptor activator’) • Longer half-life (130–140 h) than darbepoetin-α • Contains a single methoxypolyethyleneglycol (PEG) polymer of 30 kDa • Prolonged survival inthe circulation due to largemolecular mass (60 kDa) and low EPO-Rbinding affinity

  17. EPO Congeners • Hematide • A synthetic (non-recombinant) dimeric EPO mimetic peptide linked to PEG • Induces reticulocytosis and increases hemoglobin levels in healthy volunteers in phase I studies

  18. Conclusion • Improve the efficacy and pharmacokinetics of the drugs and to reduce their costs • Factors to consider: plasmids, type of promoter, marker genes, transformed host cell, production process, purification steps, posttranslational modifications, way of formulation, and immunogenicity • Safety of novel biopharmaceuticals can be proven only by clinical experience

More Related